Jayesh R. Desai
305 Grattan St
Melbourne, VIC 3000, Australia
Melbourne, VIC 3000, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 181 publications
Genomic Therapy Matching in Rare and Refractory Cancers.
Journal: JAMA oncology
Published: March 05, 2026
Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 04, 2026
CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) Fusions.
Journal: JCO precision oncology
Published: December 22, 2025
A roadmap for establishing institutional readiness for cellular therapies targeting solid tumours and autoimmune diseases.
Journal: NPJ precision oncology
Published: October 14, 2025
Exploratory biomarker analysis of RAS/BRAF somatic mutations and gene expression signatures for predicting treatment effects of aflibercept in the velour trial.
Journal: NPJ precision oncology
Published: October 07, 2025
A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 01, 2025
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial.
Journal: Nature medicine
Published: September 04, 2025
Clinical Utility of an RNA-based Gene Fusion Assay in Sarcoma for Diagnosis and Management: Experience in an Australian Laboratory.
Journal: Molecular diagnosis & therapy
Published: July 28, 2025
Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 09, 2025
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer.
Journal: The New England journal of medicine
Published: May 30, 2025
The potential benefit of encorafenib plus cetuximab with chemotherapy compared with standard of care in people with BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER study: a plain language summary.
Journal: Future oncology (London, England)
Published: May 20, 2025
Last Updated: 09/26/2026